Literature DB >> 11549659

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

J C Smith1, S Bennett, L M Evans, H G Kynaston, M Parmar, M D Mason, J R Cockcroft, M F Scanlon, J S Davies.   

Abstract

Sex hormones appear to play a pivotal role in determining cardiovascular risk. Androgen deprivation therapy for males with prostate cancer results in a hypogonadal state that may have important, but as yet undetermined, effects on the vasculature. We studied the effects of androgen deprivation therapy on large artery stiffness in 22 prostate cancer patients (mean age, 67 +/- 8 yr) over a 6-month period. Arterial stiffness was assessed using pulse-wave analysis, a technique that measures peripheral arterial pressure waveforms and generates corresponding central aortic waveforms. This allows determination of the augmentation of central pressure resulting from wave reflection and the augmentation index, a measure of large artery stiffness. Body compositional changes were assessed using bioelectrical impedance analysis. Fasting lipids, glucose, insulin, testosterone, and estradiol were measured. After a 3-month treatment period, the augmentation index increased from 24 +/- 6% (mean +/- SD) at baseline to 29 +/- 9% (P = 0.003) despite no change in peripheral blood pressure. Timing of wave reflection was reduced from 137 +/- 7 to 129 +/- 10 msec (P = 0.003). Fat mass increased from 20.2 +/- 9.4 to 21.9 +/- 9.6 kg (P = 0.008), whereas lean body mass decreased from 63.2 +/- 6.8 to 61.5 +/- 6.0 kg (P = 0.016). There were no changes in lipids or glucose during treatment. Median serum insulin rose from 11.8 (range, 5.6-49.1) to 15.1 (range, 7.3-83.2) mU/liter at 1 month (P = 0.021) and to 19.3 (range, 0-85.0 mU/liter by 3 months (P = 0.020). There was a correlation between the changes in fat mass and insulin concentration over the 3-month period (r = 0.56; P = 0.013). In a subgroup of patients whose treatment was discontinued after 3 months, the augmentation index decreased from 31 +/- 7% at 3 months to 29 +/- 5% by 6 months, in contrast to patients receiving continuing treatment in whom the augmentation index remained elevated at 6 months compared with baseline (P = 0.043). These data indicate that induced hypogonadism in males with prostate cancer results in a rise in the augmentation of central arterial pressure, suggesting large artery stiffening. Adverse body compositional changes associated with rising insulin concentrations suggest reduced insulin sensitivity. These adverse hemodynamic and metabolic effects may increase cardiovascular risk in this patient group.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549659     DOI: 10.1210/jcem.86.9.7851

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  123 in total

1.  Androgen deprivation and thromboembolic events in men with prostate cancer.

Authors:  Behfar Ehdaie; Coral L Atoria; Amit Gupta; Andrew Feifer; William T Lowrance; Michael J Morris; Peter T Scardino; James A Eastham; Elena B Elkin
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Cardiac and cognitive effects of androgen deprivation therapy: are they real?

Authors:  S M H Alibhai; H Z Mohamedali
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 4.  Energetics in colorectal and prostate cancer.

Authors:  Jeffrey A Meyerhardt; Jing Ma; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

5.  Preventing skeletal complications in androgen deprived men with prostate cancer: Time for action.

Authors:  M Braga-Basaria; S Basaria
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

6.  Adverse events associated with hormonal therapy for prostate cancer.

Authors:  Ravi J Kumar; Al Barqawi; E David Crawford
Journal:  Rev Urol       Date:  2005

7.  Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.

Authors:  May Darwish-Yassine; Manijeh Berenji; Diane Wing; Glenn Copeland; Raymond Y Demers; Carol Garlinghouse; Angela Fagerlin; Gail E Newth; Laurel Northouse; Margaret Holmes-Rovner; David Rovner; Jerry Sims; John T Wei
Journal:  J Cancer Surviv       Date:  2013-11-10       Impact factor: 4.442

8.  Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy.

Authors:  Mohammadali Mohammadzadeh Rezaei; Mohammadhadi Mohammadzadeh Rezaei; Alireza Ghoreifi; Behzad Feyzzadeh Kerigh
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

9.  Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.

Authors:  Kathryn Bylow; William Dale; Karen Mustian; Walter M Stadler; Miriam Rodin; William Hall; Mark Lachs; Supriya G Mohile
Journal:  Urology       Date:  2008-06-17       Impact factor: 2.649

10.  Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Eur Urol       Date:  2013-02-12       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.